Posted On: 01/15/2015 12:43:15 PM
Post# of 30035
Churbz: Now that the Georgetown news is out, things are making more sense. Obviously, AMBS has been negotiating with Georgetown on the price to buy their blood tests. It probably wasn't in our interests to be making large LymPro revenue projections this past month. I imagine our position was we were pioneering and didn't really know what our sales success would be, in order to keep the price more reasonable to buy them out.
Maybe this is why Gerald has kept any talk of pharma embracing us pretty low key up until now? But now that we have the deal done, as of yesterday, I wouldn't be surprised if he starts giving out more evidence of sales activity.
Lympro is open for business now and so sales and revenue will come.
How will Gerald monetize Lympro? Things are getting very interesting now that we've cornered the AD diagnostic blood test market. Our value has gone up. I suspect the intensity of the negotiations Gerald's been having with our diagnostic division will increase now that we've added Georgetown and the MS drug.
The manipulators can keep it down temporarily, but this stock price is going up before long.
Maybe this is why Gerald has kept any talk of pharma embracing us pretty low key up until now? But now that we have the deal done, as of yesterday, I wouldn't be surprised if he starts giving out more evidence of sales activity.
Lympro is open for business now and so sales and revenue will come.
How will Gerald monetize Lympro? Things are getting very interesting now that we've cornered the AD diagnostic blood test market. Our value has gone up. I suspect the intensity of the negotiations Gerald's been having with our diagnostic division will increase now that we've added Georgetown and the MS drug.
The manipulators can keep it down temporarily, but this stock price is going up before long.
(0)
(0)Scroll down for more posts ▼
